Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirational Valeant makes $500m acquisition, eyes 'Top 5' spot

This article was originally published in Scrip

Executive Summary

Valeant Pharmaceuticals is to acquire PreCision Dermatology for $475m in cash, plus an additional $25m if sales-based milestones are achieved. J Michael Pearson, CEO of Canada's largest public pharma company, announced a new "strategic initiative" last month, to become "one of the top-five most valuable pharmaceutical companies by the end of 2016."


Related Content

Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts